SHINGRIX is indicated for the prevention of herpes zoster (shingles) and post-herpetic neuralgia (PHN) in adults 50 years of age or older, and in adults 18 years of age or older at increased risk of shingles. Shingles is caused by the reactivation of the varicella zoster virus, the virus that causes chickenpox.
High Efficacy
In the pivotal studies, SHINGRIX delivered >90% efficacy in immunocompetent adults aged 50 and over.
Reduced risk of post-herpetic neuralgia (PHN)
By preventing shingles, SHINGRIX significantly reduced the risk of PHN and other complications.
2-dose Series
SHINGRIX is given as a 2-dose series. The primary vaccination schedule consists of an initial dose followed by a second dose 2 to 6 months later.
SHINGRIX is for intramuscular injection only, preferably in the deltoid muscle.
Non-live Vaccine
SHINGRIX is a non-live vaccine and is not contraindicated in immunocompromised individuals. The administration of SHINGRIX to immunocompromised subjects should be based on careful consideration of potential benefits and risks.
